The ROAR trial evaluates the combination of dabrafenib (RAF-inhibitor) and trametinib (MEK-inhibitor) in subjects with rare cancers, including SBA cases characterized by a BRAF V600E mutation, an advanced stage and no standard treatment options [17]. This evidence concerns the gene MAP2K7 and cancer.